THU0276 Efficacy and Safety of Atacicept for Prevention of Flares in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): 52-wk Data (April-SLE Trial)

D Isenberg,S Copt,D Wofsy,C Pena Rossi,C Gordon,D Licu

doi:10.1136/annrheumdis-2013-eular.804

THU0276 Efficacy and Safety of Atacicept for Prevention of Flares in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): 52-wk Data (April-SLE Trial)

D Isenberg, S Copt + Show 4 more

https://doi.org/10.1136/annrheumdis-2013-eular.804

Copy DOI

Export

Save

Cite

Journal: Annals of the Rheumatic Diseases	Publication Date: Jun 1, 2013
Citations: 4

Affiliation: University College London, Merck Serono (Switzerland), University of California, San Francisco, University of Birmingham

#Severe Systemic Lupus Erythematosus #Merck Serono #Days Of Exposure #Tx Arms #Placebo #Primary Endpoint #Fatal Pulmonary Infections #BILAG Score #SAE Rates #Proportion Of Pts

Abstract
Full-Text
Similar Papers

Abstract

Listen

BackgroundAtacicept is a fully human, recombinant fusion protein that inhibits B cell-stimulating factors APRIL and BLyS.1 Levels of these factors are raised in SLE.2ObjectivesTo evaluate efficacy and safety of atacicept...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

THU0276 Efficacy and Safety of Atacicept for Prevention of Flares in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): 52-wk Data (April-SLE Trial)